Market Cap
$3.3B
ARQT
Arcutis Biotherapeutics, Inc.
$25.16 ▼ -0.51%
Prev close $25.29Market cap$3.3B
ConsensusStrong Buy
12-mo target$37.00 (+47.1%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)25 New Institutional Positions25 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ARQT right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$2.3B
Inst. Activity
25 buys / 25 sells
Insider Activity
$0.00 buy / $2.5M sell
Insider Net $
-$2.5M
SEC Reports
16
Press Releases
1
Congressional
1 trades
Price chart 30d +6.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Feb 23, 2027 fda_pdufa
PDUFA: ARQT — ZORYVE in mild to moderate atopic dermatitis in infants aged 3 to 24 months — 2027-02-23
FDA target action date 2027-02-23 for ARQT (Arcutis Biotherapeutics, Inc.). Drug: ZORYVE. Indication
Sep 16, 2026 Insider
Matsuda Masaru sold 3,674 shares
See Remarks @ $25.00 ($91.9K)
Sep 15, 2026 Insider
Welgus Howard G. sold 4,730 shares
Director @ $24.18 ($114.4K)
Sep 15, 2026 Insider
Aug 24, 2026 SEC Welgus Howard G. acquired via exercise 1,019 shares
Director @ $7.51 ($7.7K)
Three insiders at Arcutis Biotherapeutics sold a total of $198K in open-market sales over a 7-day window, with the large
CLUSTER — Impact 2/10
Two insiders at Arcutis Biotherapeutics sold a combined $170K in open-market sales over a week. Director Welgus Howard G
CLUSTER — Impact 2/10
Two insiders at Arcutis Biotherapeutics sold a combined $299K in open-market sales over a week, with Director Welgus How
CLUSTER — Impact 2/10
Jun 30, 2026 Inst.
D. E. Shaw & — ADD
3,949,609 shares ($103.6M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 6, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 6, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 6, 2026 | Needham | MAINTAIN | Buy | 50% |
| May 7, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jun 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Price targets
Where 7 covering analysts think ARQT trades over the next 12 months.
$37.00 +47.1% upside Strong Buy
Current$25.16 Low$34.00 Median$38.00 High$40.00 7 analysts
$34.00$40.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 13 neutral · avg impact 3.0/10.Plus 1 press releases.
NEUTRALCLUSTER2/10
Three insiders at Arcutis Biotherapeutics sold a total of $198K in open-market sales over a 7-day wi
Aug 24, 2026
NEUTRALCLUSTER2/10
Two insiders at Arcutis Biotherapeutics sold a combined $170K in open-market sales over a week. Dire
Aug 22, 2026
NEUTRALCLUSTER2/10
Two insiders at Arcutis Biotherapeutics sold a combined $299K in open-market sales over a week, with
Aug 19, 2026
NEUTRAL1443/10
Patrick Burnett, an officer of Arcutis Biotherapeutics, filed a Form 144 on August 11, 2026, indicat
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Feb 23, 2027
fda_pdufa
PDUFA: ARQT — ZORYVE in mild to moderate atopic dermatitis in infants aged 3 to 24 months — 2027-02-23
FDA target action date 2027-02-23 for ARQT (Arcutis Biotherapeutics, Inc.). Drug: ZORYVE. Indication: mild to moderate atopic dermatitis in infants ag
Oct 2, 2026
other
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company
Sep 30, 2026
short_volume
Short Volume: ARQT — 55.6% short (0.3M / 0.6M)
Short: 334,083 | Exempt: 0 | TRF Vol: 600,932 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
contract
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema
Sep 29, 2026
short_volume
Short Volume: ARQT — 64.0% short (0.6M / 0.9M)
Short: 579,685 | Exempt: 0 | TRF Vol: 906,159 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.17 | $0.14–$0.20 | 186.7% | +8.6% | 3↑ 0↓ | $0.1B | 5 |
| Next Q | $0.23 | $0.03–$0.39 | 78.5% | +1.6% | 3↑ 0↓ | $0.2B | 5 |
| Current FY | $0.43 | $0.20–$0.62 | 430.8% | +4.5% | 4↑ 0↓ | $0.5B | 5 |
| Next FY | $1.36 | $1.00–$1.72 | 216.3% | +4.3% | 4↑ 0↓ | $0.7B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.172 | — |
| 7d ago | $0.158 | +0.014 |
| 30d ago | $0.158 | +0.014 |
| 60d ago | $0.078 | +0.094 |
| 90d ago | $0.076 | +0.096 |
Institutional ownership
Which big funds own ARQT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.3B total value (87,924,711 shares) as of 2026-Q2. Top holders: BlackRock,, Rubric, Polar.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 10,545,466 | $276.5M | 12.0% | — |
| Rubric Capital Management LP | 8,271,577 | $216.9M | 9.4% | — |
| Polar Capital Holdings Plc | 6,606,945 | $173.2M | 7.5% | — |
| STATE STREET CORP | 5,822,840 | $152.7M | 6.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,988,756 | $130.8M | 5.7% | — |
| MORGAN STANLEY | 4,451,014 | $116.7M | 5.1% | — |
| JENNISON ASSOCIATES LLC | 4,219,058 | $110.6M | 4.8% | — |
| D. E. Shaw & Co., Inc. | 3,949,609 | $103.6M | 4.5% | ADD +58.2% |
| UBS Group AG | 3,333,015 | $87.4M | 3.8% | — |
| BANK OF AMERICA CORP /DE/ | 2,987,431 | $78.3M | 3.4% | ADD +34.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| D. E. Shaw & Co., Inc. | ADD | 2,496,222 | 3,949,609 | +58.2% | $103.6M |
| BANK OF AMERICA CORP /DE/ | ADD | 2,221,289 | 2,987,431 | +34.5% | $78.3M |
| AMERICAN CENTURY COMPANIES INC | ADD | 1,463,228 | 1,925,031 | +31.6% | $50.5M |
| CITADEL ADVISORS LLC | DOUBLED | 15,606 | 1,160,014 | +7333.1% | $30.4M |
| Aberdeen Group plc | ADD | 645,066 | 1,098,411 | +70.3% | $28.8M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 2,226,029 | 878,426 | -60.5% | $23.0M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 503,856 | 811,752 | +61.1% | $21.3M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 49,333 | 564,072 | +1043.4% | $14.8M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 812,146 | 547,278 | -32.6% | $14.3M |
| Squarepoint Ops LLC | TRIM | 1,103,490 | 537,747 | -51.3% | $14.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$2.5M — $0.00 bought, $2.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Matsuda Masaru | See Remarks | SELL | 3,674 | $25.00 | $91.9K |
| Sep 15, 2026 | Welgus Howard G. | Director | SELL | 4,730 | $24.18 | $114.4K |
| Sep 15, 2026 | Welgus Howard G. | Director | EXERCISE | 1,019 | $7.51 | $7.7K |
| Sep 15, 2026 | Welgus Howard G. | Director | EXERCISE | 2,255 | $8.63 | $19.5K |
| Sep 15, 2026 | Welgus Howard G. | Director | EXERCISE | 822 | $6.52 | $5.4K |
| Sep 8, 2026 | Matsuda Masaru | See Remarks | SELL | 9,989 | $25.03 | $250.0K |
| Aug 27, 2026 | Curran Terrie | Director | EXERCISE | 11,148 | $7.51 | $83.7K |
| Aug 27, 2026 | Curran Terrie | Director | EXERCISE | 27,052 | $8.63 | $233.5K |
| Aug 27, 2026 | Curran Terrie | Director | SELL | 27,052 | $25.03 | $677.1K |
| Aug 27, 2026 | Curran Terrie | Director | SELL | 11,148 | $25.03 | $279.0K |
Congressional trades
ARQT trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | ARCUTIS BIOTHERAPEUTICS INC | Apr 8, 2026(37d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ARQT.
Shares short
18,458,091
Settlement Sep 15, 2026
Change vs prior
+11.5%
Semi-monthly cycle
Days to cover
8.5
At avg daily volume
Of shares outstanding
≈14.7%
Estimate — not % of float
All ARQT filing & press-release reports (17)
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 22, 2026
- CLUSTER reportAug 19, 2026
- 144 reportAug 11, 2026
- CLUSTER reportAug 6, 2026
- PRESS-RELEASE reportAug 5, 2026
- 144 reportAug 3, 2026
- PRESS-RELEASE reportJun 29, 2026
- CLUSTER reportJun 18, 2026
- 8-K reportJun 9, 2026
- CLUSTER reportMay 13, 2026
- 144 reportMay 11, 2026
- CLUSTER reportMay 6, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 15, 2026
- CLUSTER reportMar 4, 2026
- CLUSTER reportMar 4, 2026